Quick answer: FDA has approved no CJC-1295 product and no ipamorelin product. FDA's safety-risks page, current as of 2026-04-22, lists ipamorelin acetate in an active Category 2 table for outsourcing facilities and lists CJC-1295 as nominated but withdrawn, and prints safety concerns for both. We could not verify a lawful retail route to either. Whoosh does not offer them.
- FDA status
No FDA-approved product for either. Ipamorelin acetate: Category 2 (503B), added 2023-09-29. CJC-1295: nominated but withdrawn (previously Category 2).
- Lawful route
None we could confirm for either. Only a prescriber's own judgment or a registered trial might apply.
- Brand or compounded
Neither has a brand drug. A compounded version of either is not FDA-approved.
- Whoosh offers this
No
As of 2026-10-07.
People search for these two together because they are often sold together. This page does not point to any seller. It reports what FDA's pages say about each substance, what they imply for the routes people ask about, and what we could not confirm. Our partner for the prescription route does not offer either product, and nothing here links to a seller.
What each one is
CJC-1295 is described in an FDA briefing as a 29 amino acid peptide. WADA's list groups it with growth hormone releasing factors and groups ipamorelin with growth hormone secretagogues. We found no approved drug that contains either one, alone or combined.
The approved relatives are different substances. Tesamorelin (Egrifta) is approved for reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy, and its label says it is not indicated for weight loss management, as read on the label dated 2026-07-29. Sermorelin's earlier approval was withdrawn effective 2009-06-18. Neither approval transfers to CJC-1295 or ipamorelin. See fda-approved peptides.
What FDA's pages say
Ipamorelin. FDA's safety-risks page (current as of 2026-04-22) lists ipamorelin acetate in the active Category 2 table for outsourcing facilities, added 2023-09-29, and also in the withdrawn table. FDA says Category 2 means it has identified significant safety risks. The page says a study published in the literature identified serious adverse events, including death, when ipamorelin was given intravenously for improving gastric motility. It says FDA has not identified safety information for certain other injectable routes. It also cites a risk of immunogenicity, because of the potential for aggregation or peptide-related impurities. FDA's briefing for its 2024-10-29 advisory meeting says these formulations are increasingly marketed by medical spas and wellness clinics.
CJC-1295. The same page lists CJC-1295 in the "nominated but withdrawn" table, which FDA introduces as substances previously in Category 2 that were withdrawn by the nominators. We do not write that CJC-1295 is in Category 2 today, and we do not write that it is banned. The page still prints FDA's concerns: immunogenicity for certain routes, peptide-related impurities, and serious adverse events that FDA associates with CJC-1295, such as a faster heart rate and a systemic vasodilatory reaction, and says clinical data are limited. FDA's category document for 503A compounding (updated 2026-05-14) lists neither substance in any category.
"Category 2" is FDA's label for bulk substances it has identified as presenting significant safety risks while it evaluates them. FDA says it would consider taking action against a compounder that uses such a substance. Our compounded peptides guide explains the 503A and 503B categories in plain words.
No approved product. We found no approved CJC-1295 or ipamorelin product, and no FDA statement saying either is lawful to sell as a drug.
Anti-doping. WADA's 2026 Prohibited List, as read in a copy hosted by the International Testing Agency, names CJC-1295 under growth hormone releasing factors and ipamorelin under growth hormone secretagogues. Athletes in tested sports should check the current list.
Context from a medical society. The Endocrine Society's 2023 scientific statement on hormones and aging says growth hormone releasing hormone and its secretagogues are "not approved" as anti-aging agents. It is about that use, not about every use, and not about these two products by name.
Products sold as "research" blends
FDA's warning letters (for example, the letter dated 2026-08-24 cited below) describe sellers offering blends of these peptides under research labels. One letter names a tesamorelin and ipamorelin blend among the products it calls unapproved new drugs. FDA says that despite labels stating the products are not intended for human use, the website evidence shows they are "intended to be drugs for human use." We describe these only as blends marketed as research products, and we do not name any seller.
FDA also says that the sale of a diluent and a calculator alongside such products was part of the evidence of intended use. We do not explain how to prepare or use any product. The point is that FDA read the whole offer, not just the label.
What lawful routes exist
We could not verify a retail route. Route by route:
- A prescription from your own prescriber. Compounded drugs are not FDA-approved, and FDA says it does not review them for safety, effectiveness or quality before they are marketed. Whether a particular pharmacy may lawfully compound ipamorelin or CJC-1295 today was not stated in any FDA sentence we read. For ipamorelin, FDA's Category 2 listing means FDA says it would consider enforcement. A prescriber and a state-licensed pharmacy can tell you their position in writing.
- A clinical trial. You can search a registry such as ClinicalTrials.gov for studies of either substance. We make no claim that any trial is open to you.
- A "research" website. This is where most searches lead, and it is the route FDA's letters address. FDA's importation guidance for individuals is that bringing such drugs in for personal use is, in most cases, unlawful.
See is it legal to buy peptides online for the wider picture.
The five criteria applied
Our five criteria ask for a prescriber, a licensed pharmacy, plain status, fair pricing and no research label. A product sold as a research blend fails the fifth. A seller that says "FDA-approved" about either substance would be wrong, because we found no approved product.
Whoosh does not offer these
Whoosh does not offer CJC-1295 or ipamorelin. As stated by Whoosh (read 2026-10-07), it offers compounded sermorelin, semaglutide and tirzepatide, plus NAD+, glutathione and a topical GHK-Cu product; it does not offer BPC-157, CJC-1295, ipamorelin, tesamorelin or retatrutide. Compounded medications are not FDA-approved. The Whoosh Wellness review covers what it does offer; this page has no button.
What to ask a prescriber
Ask what FDA status the product has, what FDA's safety text says about it, whether a label exists, who compounded it, which state licenses that pharmacy, and who answers questions after it arrives. If the answers are vague or only verbal, take that as information about the seller. Our safety guide explains what a label tells you that a product page does not.
Sources
- FDA: Certain bulk drug substances for use in compounding that may present significant safety risks page current as of 2026-04-22, read 2026-10-07
- FDA: Bulk drug substances used in compounding under section 503A category document updated 2026-05-14, read 2026-10-07
- FDA: Briefing document for the 2024-10-29 Pharmacy Compounding Advisory Committee meeting memo dated 2024-08-19, read 2026-10-07
- FDA warning letter dated 2026-08-24 read 2026-10-07
- FDA: Personal importation page current as of 2025-08-18, read 2026-10-07
- DailyMed: Egrifta WR label label effective 2026-07-29, read 2026-10-07
- Endocrine Society scientific statement on hormones and aging 2023, read 2026-10-07
FAQ
Are CJC-1295 and ipamorelin FDA-approved?
No. We found no approved product containing either.
Is ipamorelin in FDA's Category 2?
FDA's safety-risks page, current as of 2026-04-22, lists ipamorelin acetate in the active Category 2 table for outsourcing facilities, added 2023-09-29, and also repeats it in the withdrawn table. FDA's pages and PDFs are the controlling text.
Is CJC-1295 banned?
We do not use that word. FDA's page lists it as nominated but withdrawn, previously in Category 2, and prints safety concerns for it.
Can I buy them from a research site legally?
FDA's warning letters call products of this kind unapproved new drugs, and FDA says labels about research use do not change what the product is. FDA's personal importation page says importing drugs for personal use is illegal in most circumstances.
Does Whoosh offer either one?
No. As stated by Whoosh (read 2026-10-07), it does not offer CJC-1295 or ipamorelin.
Are they allowed in sports?
WADA's 2026 Prohibited List names both. Check the current list before any use.
Not medical advice. See the medical disclaimer.
